EVAX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.85%, SMA50 -23.16%, SMA200 -17.66%). The stock’s 14-day RSI is 41.37 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.25% below its high and over 170.83% above its low. Average 10-day trading volume of 15.76 thousand shares is below the 3-month average of 26.46 thousand, indicating normal recent market interest.

Evaxion Biotech A/S has 6.32 million shares outstanding. The public float is 177.29 million shares, elevated short interest at 2.47% of float. This equals 117.81 thousand shares. The short ratio is 1.03 days. Institutional investors hold 11.39% of the float. Insiders own 17.47%.

Evaxion Biotech A/S last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.34. This means the shares are trading below this model’s fair value.

Evaxion Biotech A/S (NASDAQ:EVAX) closed at $3.09 USD, gaining $0.07 (2.25%) from the previous close of $3.02. The stock is currently mid-range between its 52-week high and low $2.45 and $12.15. With a market capitalization of about $19.50 million, Evaxion Biotech A/S is classified as a micro-cap and shows lower-than-market volatility (beta ~0.26). Key stats such as the average daily volume over the past year has been around 26.95 thousand shares, volume is running light vs its 52-week average. Headquartered in Horsholm, ND, Evaxion Biotech A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Helen Katrina Tayton-Martin, the company employs approximately 46 people and listed since February 05, 2021. Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies.

Evaxion Biotech A/S generated EPS of -$5.96 over the past year. Five-year average earnings growth is 22.22%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $10.00. The high target offers 429.8% upside. The low target suggests 231.13% downside. The mean target is $13.71. This offers 353.97% upside. Evaxion Biotech A/S earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 4300.0%. The prior quarter beat by 308.16%. Over the last six quarters, Apple has recorded several small beats. These include -87.1% in October 31, 2024.

Evaxion Biotech A/S trades at a P/E ratio of -1.96, slightly below the S&P 500 average, with a price-to-sales ratio of 2.52 and a price-to-book ratio of 1.89 suggesting the stock is closer to book value. The P/FCF stands at 0.0, also above market averages.

Our AI price prediction model suggests that Evaxion Biotech A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.95%, with price expected at $2.78 by August 04, 2026, within a range of $2.62 to $2.94 3-Month Outlook: Projected fall of -18.87%, reaching $2.45 by October 19, 2026, with a range of $2.12 to $2.76. 1-Year Outlook: Projected loss of -21.52%, with price at $2.37 by July 21, 2027, within a range of $0.00 to $1.00.

Evaxion Biotech A/S (NASDAQ:EVAX) shares are flat -1.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Evaxion Biotech A/S trading at a premium to the broader market with a P/E of -1.96. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.56, suggesting 315.89% upside. Our AI forecast model points to short-term weakness (-7.95% over two weeks), a medium-term fall (-18.87% over three months), and a longer-term loss (-21.52% over one year), with expected trading ranges indicating moderate volatility.